M D Abeloff
Overview
Explore the profile of M D Abeloff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
1147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gradishar W, STEPHENSON P, Glover D, Neuberg D, Moore M, Windschitl H, et al.
Cancer
. 2001 Dec;
92(10):2517-22.
PMID: 11745184
Background: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma. Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of...
2.
Bos R, Zhong H, Hanrahan C, Mommers E, Semenza G, Pinedo H, et al.
J Natl Cancer Inst
. 2001 Feb;
93(4):309-14.
PMID: 11181778
Background: Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates gene expression in critical pathways involved in tumor growth and metastases. In this report, we investigated whether the level of...
3.
Wolff A, Abeloff M
Surg Oncol
. 2000 Mar;
8(2):93-101.
PMID: 10732961
In the last three decades, there has been a gradual, though significant change in the treatment of early stage breast cancer. For almost a century, physicians advocated an "anatomical view"...
4.
Kucuk O, Pandya K, Skeel R, Hochster H, Abeloff M
Breast Cancer Res Treat
. 1999 Dec;
57(2):201-6.
PMID: 10598047
Purpose: The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer. Methods: Thirty-six women with recurrent...
5.
Shipp M, Abeloff M, Antman K, Carroll G, Hagenbeek A, Loeffler M, et al.
J Clin Oncol
. 1999 Aug;
17(1):423-9.
PMID: 10458261
No abstract available.
6.
Subramanyan S, Abeloff M, Bond S, Davidson N, Fetting J, Gordon G, et al.
Cancer Chemother Pharmacol
. 1999 May;
43(6):497-502.
PMID: 10321510
Purpose: This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with...
7.
Mikhak B, Zahurak M, Abeloff M, Fetting J, Davidson N, Donehower R, et al.
Cancer
. 1999 Mar;
85(4):899-904.
PMID: 10091768
Background: A Phase II study was performed evaluating the disease free and overall survival rates associated with a dose-intensive, 16-week, doxorubicin-based adjuvant chemotherapy regimen in women with breast carcinoma and...
8.
Shipp M, Abeloff M, Antman K, Carroll G, Hagenbeek A, Loeffler M, et al.
Ann Oncol
. 1999 Mar;
10(1):13-9.
PMID: 10076716
No abstract available.
9.
Fetting J, Gray R, Fairclough D, Smith T, Margolin K, Citron M, et al.
J Clin Oncol
. 1998 Jul;
16(7):2382-91.
PMID: 9667255
Purpose: The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF). The 16-week regimen features greater doxorubicin and 5-FU...
10.
FALKSON G, Gelman R, Pandya K, Osborne C, Tormey D, CUMMINGS F, et al.
J Clin Oncol
. 1998 May;
16(5):1669-76.
PMID: 9586877
Purpose: To investigate the value of maintenance treatment for patients with metastatic breast cancer whose disease is in complete remission (CR). Patients And Methods: One hundred ninety-five women (141 eligible)...